N- (3-methoxy-5-methylpyrazin-2-yl)-2-(4-' 1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent
Details for Australian Patent Application No. 2003255835 (hide)
International Classifications
Event Publications
6 November 2003 Complete Application Filed
Priority application(s): 0219660.8 23.08.02 GB
22 April 2004 Application Open to Public Inspection
Published as AU-B-2003255835
5 April 2007 Application Accepted
Published as AU-B-2003255835
17 May 2007 Corrigenda
Applications Accepted - Name Index Under the name AstraZeneca AB, Application No. 2003255835, under INID (54), correct the title to read N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulpho as an anticancer agent
2 August 2007 Standard Patent Sealed
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser